Lifeward Q2 revenue skyrockets 16% to $6.6 million
Full story: https://grafa.com/en/news/united-states/lifeward-q2-2026-revenue-6-6-million
-
Lifeward reported Q2 2026 revenue of $6.62 million, up 16% year-over-year, while adjusted loss was $1.46 per share.
-
Adjusted EPS beat the Zacks estimate by 2.01%, although revenue missed the consensus estimate by 10.74%.
-
Lifeward ended June with $9.4 million in cash and said it expects revenue momentum to continue during the second half of 2026.
Lifeward (NASDAQ:LFWD) reported Q2 2026 revenue of $6.62 million, up 16% year-over-year, while adjusted loss was $1.46 per share.
The adjusted loss beat the Zacks consensus estimate of $1.49 by 2.01%, while revenue missed its consensus estimate by 10.74%.
GAAP net loss was $11.5 million, gross margin fell to 41% from 44%, and unrestricted cash reached $9.4 million.
Lifeward said it expects revenue momentum to continue in H2.
Elsewhere, ReWalk Personal exoskeleton sales increased 13% to $2.5 million, while AlterG products and services revenue rose 25% to $4.1 million.
Lifeward also secured up to $11.2 million of strategic financing in July and launched an Ottobock Care pilot to expand ReWalk access.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
